Presentation is loading. Please wait.

Presentation is loading. Please wait.

Response rates for patients achieving 50% (A), 70% (B), and 90% (C) improvement in ACR criteria, and normal physical function (D) over the course of 10.

Published byMaja Hald Modified over 5 years ago

Similar presentations

Presentation on theme: "Response rates for patients achieving 50% (A), 70% (B), and 90% (C) improvement in ACR criteria, and normal physical function (D) over the course of 10."— Presentation transcript:

1 Response rates for patients achieving 50% (A), 70% (B), and 90% (C) improvement in ACR criteria, and normal physical function (D) over the course of 10 years of treatment. Response rates for patients achieving 50% (A), 70% (B), and 90% (C) improvement in ACR criteria, and normal physical function (D) over the course of 10 years of treatment. Lines with symbols represent observed response rate based on all randomized patients (n = 268, 274, and 257 for adalimumab + MTX, adalimumab, and MTX, respectively). Dashed lines represent response rate using nonresponder imputation based on all patients entering open-label extension (n = 183, 159, and 155 for adalimumab + MTX, adalimumab, and MTX, respectively). Bar graphs reflect data as observed at final visit using last observation carried forward method for all randomized patients (n = 268, 274, and 257 for adalimumab + MTX, adalimumab, and MTX, respectively). ACR: American College of Rheumatology Criteria response; ADA: adalimumab; MTX: methotrexate; HAQ-DI: Health Assessment Questionnaire–Disability Index. Edward C. Keystone et al. J Rheumatol 2014;41:5-14 ©2014 by The Journal of Rheumatology

Download ppt "Response rates for patients achieving 50% (A), 70% (B), and 90% (C) improvement in ACR criteria, and normal physical function (D) over the course of 10."

Similar presentations

A NEW LOOK AT RA Interactive Hot Topics Series

A NEW LOOK AT RA Interactive Hot Topics Series
Volume 18, Issue 2, Pages (March 2015)

Volume 18, Issue 2, Pages (March 2015)
Clinical evaluation of recombinant human platelet – derived growth factor for the treatment of lower extremity diabetic ulcers  David L. Steed, MD, the.

Clinical evaluation of recombinant human platelet – derived growth factor for the treatment of lower extremity diabetic ulcers  David L. Steed, MD, the.
Proportion of patients reporting scores ≥age-matched and gender-matched normative PRO values at baseline and 24 weeks in the (A) AMBITION and (B) ADACTA.

Proportion of patients reporting scores ≥age-matched and gender-matched normative PRO values at baseline and 24 weeks in the (A) AMBITION and (B) ADACTA.
Claus Bachert, PhD, Ana R. Sousa, PhD, Valerie J. Lund, MD, Glenis K

Claus Bachert, PhD, Ana R. Sousa, PhD, Valerie J. Lund, MD, Glenis K
Mean change from baseline in (A) DAS28-4(ESR), (B) CDAI and (C) HAQ-DI

Mean change from baseline in (A) DAS28-4(ESR), (B) CDAI and (C) HAQ-DI
Change in secondary endpoints over time: (A) LS mean change from baseline in DAS28-CRP through Week 32, (B) mean change from baseline in CRP through Week.

Change in secondary endpoints over time: (A) LS mean change from baseline in DAS28-CRP through Week 32, (B) mean change from baseline in CRP through Week.
Mean change in patient-reported outcomes from baseline to Week 25 with biweekly or monthly pegloticase compared with placebo. Mean change in patient-reported.

Mean change in patient-reported outcomes from baseline to Week 25 with biweekly or monthly pegloticase compared with placebo. Mean change in patient-reported.
Disease activity over time in autoantibody-positive patients treated with belimumab. Disease activity over time in autoantibody-positive patients treated.

Disease activity over time in autoantibody-positive patients treated with belimumab. Disease activity over time in autoantibody-positive patients treated.
TNT post hoc analysis: Improvement between baseline and final visit in estimated GFR by treatment group End point 10-mg atorvastatin 80-mg atorvastatin.

TNT post hoc analysis: Improvement between baseline and final visit in estimated GFR by treatment group End point 10-mg atorvastatin 80-mg atorvastatin.
Radiographic progression among three therapy groups (triple therapy group, anti-TNF treatment group and MTX responders) stratified by MBDA categories at.

Radiographic progression among three therapy groups (triple therapy group, anti-TNF treatment group and MTX responders) stratified by MBDA categories at.
Benefit-risk balance. Benefit-risk balance. Predicted probabilities of developing serious infection versus predicted probabilities of achieving Boolean-based.

Benefit-risk balance. Benefit-risk balance. Predicted probabilities of developing serious infection versus predicted probabilities of achieving Boolean-based.
Percentage of patients achieving minimal disease activity (MDA): A

Percentage of patients achieving minimal disease activity (MDA): A
ACR20, ACR50, and ACR70 response rates during the 12-week study of Japanese patients with rheumatoid arthritis treated with baricitinib or placebo. ACR20,

ACR20, ACR50, and ACR70 response rates during the 12-week study of Japanese patients with rheumatoid arthritis treated with baricitinib or placebo. ACR20,
Percentage of patients achieving DAS28 (CRP) < 3

Percentage of patients achieving DAS28 (CRP) < 3
Amy S. Paller, MD, Elaine C. Siegfried, MD, David M

Amy S. Paller, MD, Elaine C. Siegfried, MD, David M
Percentages of (A) ACR 20, 50, and 70 responders, and (B) patients with DAS28-CRP ≤ 3.2 or < 2.6 during 5 years. Percentages of (A) ACR 20, 50, and 70.

Percentages of (A) ACR 20, 50, and 70 responders, and (B) patients with DAS28-CRP ≤ 3.2 or < 2.6 during 5 years. Percentages of (A) ACR 20, 50, and 70.
Updated 2016 PsA Core Domain Set.

Updated 2016 PsA Core Domain Set.
Changes in the proportion (95% CI) of patients with (A) fatal events, (B) serious infections, (C) malignancy, (D) GI perforation, and (E) serious cardiac.

Changes in the proportion (95% CI) of patients with (A) fatal events, (B) serious infections, (C) malignancy, (D) GI perforation, and (E) serious cardiac.
Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with difficult-to-treat nail and scalp psoriasis: Results of 2 phase III randomized, controlled.

Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with difficult-to-treat nail and scalp psoriasis: Results of 2 phase III randomized, controlled.

Similar presentations

Ads by Google